sacituzumab govitecan
gilead sciences
['neostar', 'tnbc', 'sacituzumab', 'brca']
 neostar trial: 4 cycles of sacituzumab govitecan as single agent in neoadjuvant setting in tnbc reached: - pcr 30% in all population - pcr 75% in gbrca
small sample size but intriguing data. #asco22 #bcareporter 